


Searching News Database: CD47
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
HSMN NewsFeed - 4 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
